GeneReach Biotechnology - Asset Resilience Ratio
GeneReach Biotechnology (4171) has an Asset Resilience Ratio of 28.34% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how GeneReach Biotechnology's Asset Resilience Ratio has changed over time. Check GeneReach Biotechnology (4171) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down GeneReach Biotechnology's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of GeneReach Biotechnology.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$249.69 Million | 28.34% |
| Total Liquid Assets | NT$249.69 Million | 28.34% |
Asset Resilience Insights
- Very High Liquidity: GeneReach Biotechnology maintains exceptional liquid asset reserves at 28.34% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
GeneReach Biotechnology Industry Peers by Asset Resilience Ratio
Compare GeneReach Biotechnology's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
Annual Asset Resilience Ratio for GeneReach Biotechnology (2018–2025)
The table below shows the annual Asset Resilience Ratio data for GeneReach Biotechnology.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 28.34% | NT$249.69 Million ≈ $7.87 Million |
NT$881.05 Million ≈ $27.76 Million |
-8.56pp |
| 2024-12-31 | 36.90% | NT$393.49 Million ≈ $12.40 Million |
NT$1.07 Billion ≈ $33.60 Million |
+10.11pp |
| 2023-12-31 | 26.79% | NT$315.10 Million ≈ $9.93 Million |
NT$1.18 Billion ≈ $37.05 Million |
+25.84pp |
| 2022-12-31 | 0.95% | NT$15.36 Million ≈ $483.77K |
NT$1.62 Billion ≈ $51.10 Million |
+0.13pp |
| 2021-12-31 | 0.82% | NT$13.84 Million ≈ $436.04K |
NT$1.68 Billion ≈ $53.07 Million |
-2.62pp |
| 2020-12-31 | 3.44% | NT$42.72 Million ≈ $1.35 Million |
NT$1.24 Billion ≈ $39.08 Million |
-30.26pp |
| 2018-12-31 | 33.70% | NT$233.82 Million ≈ $7.37 Million |
NT$693.83 Million ≈ $21.86 Million |
-- |
About GeneReach Biotechnology
GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. The company offers various equipment, such as POCKIT Central Nucleic Acid Analyzer, POCKIT Micro Series, taco mini Automatic Nucleic Acid Extraction System, taco Prep Homogenization System, and cubee Mini-Centrifuge; reagents and consumables, including Human IVD Assa… Read more